rttnews.com
Cure8 news brief
Why This Matters
The article reports Phase 3 post‑hoc analyses showing that mirikizumab (Omvoh) produced higher rates of composite, multidimensional remission measures in UC and Crohn’s disease versus placebo, which could matter to patients seeking treatments that combine symptom relief with objective healing and steroid avoidance.
Who Should Pay Attention
Adults with UC or Crohn’s disease, patients who failed prior biologics, clinicians treating IBD, and IBD researchers.
Study Snapshot
Story typeBusiness news
Evidence typePhase 3 clinical trial
Source depthFull source text
What To Know
This item summarizes company‑reported, post‑hoc trial analyses rather than new randomized primary endpoint results. The reported composite outcomes combine symptoms, objective inflammation measures (biopsy/endoscopy, biomarkers), and steroid avoidance; proportions were higher with Omvoh than placebo in the presented analyses.
Safety from the underlying Phase 3 programs has been reported previously, and Lilly notes ongoing studies including combination approaches and pediatric trials.
These findings suggest that some patients on mirikizumab may achieve multidimensional remission including symptom relief and objective healing, but because the results are post‑hoc they are hypothesis‑generating rather than definitive for changing care.
Keep In Mind
Findings are from post‑hoc analyses of Phase 3 trials reported by the company and will be presented at UEG Week 2026; post‑hoc results are hypothesis‑generating and not equivalent to prespecified primary endpoint confirmations.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationrttnews.com
AuthorsRTTNews Staff Writer
Indexed viaGoogle News
Source typeWeb article
PublishedOct 15, 2026, 3:18 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Lilly Reports Positive Two-Year VIVID-2 Study Results For Omvoh In Crohn's Disease
Durable treatment responses matter to people with Crohn’s disease because sustained clinical remission and endoscopic improvement can mean fewer symptoms and less inflammation over time. Longer safety and durability data...
Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s ...
Early Phase 1 findings suggest a gut-targeted PDE4 prodrug may engage its target in diseased tissue and produce early improvements in symptoms, endoscopy, and tissue inflammation — findings that, if confirmed in Phase 2,...
Anti-TL1A duvakitug demonstrates 'robust' response in Crohn's disease, ulcerative colitis
The study tests a new mechanism (TL1A inhibition) that may reduce inflammation and fibrosis in IBD. Positive phase 2b results suggest duvakitug could become another treatment option if later trials confirm benefit and...